Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842254 · ClinicalTrials.gov registry record · Early Phase 1
Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03842254: Completed Early Phase 1 study, sponsored by Northwestern University.
NCT03842254 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03842254, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study evaluates the effect of erythropoietin on the number and function of regulatory T cells in adults with autoimmune hepatitis. Participants will receive a single dose of erythropoietin, and then the investigators will collect blood at different time points for analysis of regulatory T cell number and function.
Primary Outcome
Calculated relative to baseline collected at time of enrollment
Interventions
- DRUG Erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2021-02-18 |
| Phase | Early Phase 1 |
What the finished NCT03842254 record still lists
NCT03842254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Erythropoietin is the first listed.
NCT03842254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03842254 about?
NCT03842254 is a clinical study titled "Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease". This study evaluates the effect of erythropoietin on the number and function of regulatory T cells in adults with autoimmune hepatitis. Participants will receive a single dose of erythropoietin, and then the investigators will collect blood at different time points for analysis of regulatory T cell ...
What is the current status of trial NCT03842254?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-01-25. Estimated completion is 2021-02-18.
What interventions are being tested in trial NCT03842254?
The interventions under investigation include: Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT03842254?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03842254's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI